Propranolol‐resistant infantile hemangioma successfully treated with sirolimus
Victoria Lucía Dávila Osorio, Helena Iznardo, Esther Roé, L. Puig, Eulàlia Baselga
Abstract
Infantile hemangiomas are the most common benign vascular tumors in childhood. Propranolol is the first-line treatment for infantile hemangiomas, but failures may occur. Sirolimus, an mTOR inhibitor, is a promising drug for the treatment of vascular malformations and vascular tumors. We present the case of a child with multiple infantile hemangiomasthat was successfully treated with sirolimus and propranolol after failure of combined propranolol and prednisolone treatment.
Topics & Concepts
PropranololMedicineSirolimusHemangiomaPrednisoloneInfantile hemangiomaDiscovery and development of mTOR inhibitorsVascular TumorsInternal medicineSurgeryPI3K/AKT/mTOR pathwayApoptosisBiochemistryChemistryVascular Malformations and HemangiomasTumors and Oncological CasesTuberous Sclerosis Complex Research